SEC Form 4 · accession 0001193125-26-359636
Viridian Therapeutics, Inc.\DE · VRDN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jennifer Tousignant
Officer — Chief Legal Officer
Period of report
Aug 19, 2026
Accepted (ET)
Aug 20, 2026 · 8:05 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001590750
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 19, 2026 | S | 4,212 | $24.50 | D | 0 | D | |
| Common Stock | Aug 19, 2026 | M | 10,000 | $14.41 | A | 10,000 | D | |
| Common Stock | Aug 19, 2026 | S | 10,000 | $24.50 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $14.41 | Aug 19, 2026 | M | 10,000 | D | — | Mar 3, 2035 | Common Stock | 10,000 | 114,072 | D |
Explanation of responses
- F1The shares sold include 718 shares previously acquired by the reporting person pursuant to the Viridian Therapeutics, Inc. Employee Stock Purchase Plan in a transaction that was exempt under Rule 16b-3(c).
- F2The option was granted on March 3, 2025 and vests in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date.